Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A comprehensive, neutral analysis of the global cancer cell therapy landscape; 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials
Cancer Research Institute iAtlas Poised to Improve Patient Outcomes by Providing Researchers Greater Access to Genomics Data
Two leading non-profits combine efforts to accelerate cancer immunotherapy for patients globally
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Dr. Lieping Chen's work helped pave the way for the development of the PD-1/PD-L1 checkpoint immunotherapies that have revolutionized cancer care.
Scientist Thomas Tan discusses his preparation for the Bigfoot 100K and his motivation for fundraising for cancer immunotherapy research.